Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human IGFBP4 Antibodies:
anti-Mouse (Murine) IGFBP4 Antibodies:
anti-Rat (Rattus) IGFBP4 Antibodies:
Go to our pre-filtered search.
Human Polyclonal IGFBP4 Primary Antibody for ELISA, WB - ABIN408729
Durai, Davies, Yang, Yang, Seifalian, Goldspink, Winslet: Biology of insulin-like growth factor binding protein-4 and its role in cancer (review). in International journal of oncology 2006
Show all 2 Pubmed References
Cow (Bovine) Polyclonal IGFBP4 Primary Antibody for IHC, WB - ABIN2782316
Durai, Yang, Sales, Seifalian, Goldspink, Winslet: Increased apoptosis and decreased proliferation of colorectal cancer cells using insulin-like growth factor binding protein-4 gene delivered locally by gene transfer. in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2007
Show all 2 Pubmed References
Human Polyclonal IGFBP4 Primary Antibody for IHC, IHC (p) - ABIN4894624
Davila, Laws, Kannan, Li, Taylor, Bagchi, Bagchi: Rac1 Regulates Endometrial Secretory Function to Control Placental Development. in PLoS genetics 2015
The authors also identified single-nucleotide polymorphisms in NRP2 (show NELL2 Antibodies) and IGFBP4 loci that increase and reduce risk of lichen planus in hepatitis C virus-infected patients, respectively.
the results of this study raise the possibility that human mesenchymal stem cells actions involve a negative-regulatory mechanism that suppresses Treg proliferation by releasing IGFBP-4
IGFBP-4 maybe act as a potential negative regulator in the progression of lung cancer through downregulation of COX-2 (show COX2 Antibodies).
Patients with type 2 Diabetes Mellitus had lower serum concentrations of IGFBP-4 compared to controls.
Data show that insulin-like growth factor binding protein-4 (IGFBP-4) was significantly elevated in lupus nephritis, particularly those with renal pathology chronicity changes.
The present study provides the first evidence that apoptosis inhibitor of macrophages binds to IGFBP2 (show IGFBP2 Antibodies), 3 and 4.
Data show that co-transfection with cDNA encoding stanniocalcin-1 (show STC1 Antibodies) abrogates the proteolytic activity of pregnancy-associated plasma protein-A (PAPP-A (show PAPPA Antibodies)) toward IGF-binding protein 4 (IGFBP-4).
PLasma IGFBP-4 levels are not acutely altered following myocardial infarction treated with heparin and percutaneous coronary intervention.
High IGFBP-4 fragment levels were associated with increased all-cause and cardiovascular mortality rates in T1D patients with and without diabetic nephropathy.
Data indicate co-localization of insulin (show INS Antibodies)-like growth factor binding proteins IGFBP-4, IGFBP-5 (show IGFBP5 Antibodies) in the syncytiotrophoblast layer of first trimester placental villi as early as 5 weeks of gestational age.
Igfbp4 is required for inguinal fat expansion in female mice but not in male mice. However, gonadal WAT expansion, which is prevented by estrogen during high-fat diet, does not require Igfbp4.
IGFBP-4 modulates the skeleton in a gender-specific manner, acting as both a cell autonomous and cell non-autonomous factor.
exerts a negative effect on basal intestinal growth but plays a positive regulatory role in the intestinotropic actions of GLP-2
IGF-1 (show IGF1 Antibodies)/IGFbp4 signaling regulated the post-developmental adipose tissue expansion.
Igfbp2 (show IGFBP2 Antibodies)-5 are expressed in distinct and complementary patterns during cochlear development.
SOX9 (show SOX9 Antibodies) is a transcriptional regulator of IGFBP-4 and that SOX9 (show SOX9 Antibodies)-induced activation of IGFBP-4 may be one of the mechanisms by which SOX9 (show SOX9 Antibodies) suppresses cell proliferation and progression of colon cancer.
findings indicate that the defect in p53 function and the increased proteolysis of IGFBP-4, we had observed, represent two components of the same pathway, which contributes to the oncogenic function of Skp2B
Inactivation of IGFBP4 diminished the anabolic effects of PAPP-A (show PAPPA Antibodies) on bone.
Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice
IGFBP-4 is a potential growth inhibitor of lymphoid tissues.
IGFBP4 maternal blood concentrations were lower during pregnancy than during non-pregnant cycles and synchronized control cycles. The lower IGFBP4 in maternal blood may result in an increase of free insulin (show INS Antibodies)-like growth factor- for local action.
follicular dominance was associated with low or decreased follicular fluid concentrations of IGFBP-4 and -5
Sequence analysis showed that the porcine IBP4 gene encodes a protein of 259 amino acids which shares high homology with the insulin-like growth factor binding protein 4 (IBP4) of eight species.
This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma in both glycosylated and non-glycosylated forms. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors.
insulin-like growth factor binding protein 4
, IGF-binding protein 4
, insulin-like growth factor-binding protein 4
, Band 3A
, differentially expressed in B16F10 2
, insulin-like growth factor binding protein-4